See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Kelly Close

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Diabetes and Actos

Page 2
Actos and Avandia Cost Plenty
Oct 10, 2007 | 
According to Greek researchers, Actos and Avandia were behind a tripling of the cost of medicines used to treat Athenians with type 2 diabetes over the past eight years.
Actos and Avandia: New Heart Risk Studies
Oct 5, 2007 | 
The September 2007 Journal of the American Medical Association (JAMA) has published two new studies, one a meta-analysis of Avandia (rosiglitazone) and the other a meta-analysis of Actos (pioglitazone).
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

World Diabetes Day 2009

DHTV Covers World Diabetes Day in Sacramento, California

World Diabetes Day 2009

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Kelly Close

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Amid Accusatory Debate, FDA Puts Black Box Warning on Avandia and Actos
Jul 12, 2007 | 
In a congressional hearing on June 13, 2007, the Food and Drug Administration (FDA) revealed that it has called for a black box warning, the sternest possible, on both Actos and Avandia.
Updated: Analysis Associates Avandia With Greater Risk of Heart Attack
May 31, 2007 | 
Analysis of several recent studies indicates that Avandia (rosiglitazone), a type 2 diabetes medication that's been taken by more than six million people worldwide, is associated with a 43 percent increased risk of heart attack and with a borderline-significant increased risk of heart attack-related death.
Oral Meds Research
Sep 1, 2006 | 
Starlix Found to Reduce Liver Fat
Is Pargluva On the Ropes?
Jan 1, 2006 | 
It was the belle of the ball at last summer’s ADA Scientific Sessions in San Diego. Now it appears that muraglitazar (Pargluva) is clinging to life after a scathing report recently published by the Journal of the American Medical Association.
ACTOplus Met Approved by the FDA for Type 2 Diabetes
Nov 1, 2005 | 
In August 2005, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved ACTOplus Met for the treatment of type 2 diabetes.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.